Detail akcie GENOMED online

Business Summary: Genomed SA is a Poland-based company engaged in genetic research. It develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The Company also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, GENOMED SA revenues increased 28% to PLN20.3M. Net income totaled PLN1.7M vs. loss of PLN436K. Revenues reflect Sale of Products increase of 29% to PLN19.9M, Sale of Goods and Materials increase of 6% to PLN412K. Net Income reflects Other Financial Expense decrease of 29% to PLN89K (expense), Other Income increase of 91% to PLN76K (income), Interest Income - Non-Bank increase from PLN0K to PLN14K (income).